Federal Official Gazette
No updates.
ANS news
Cosaúde holds its 46th technical meeting
Nov 25, 2025
Discussion of the proposals for inclusion in the List of Health Procedures and Events (Rol) and analysis of public participation concerning the following technologies:
SESSION
TECHNOLOGY
INDICATION FOR USE
9am to 12pm
UAT 167 – Guselcumab
(Analysis of the Public Participation contributions)
Treatment of adult patients with moderate to severe ulcerative colitis (a chronic inflammatory bowel disease that can cause diarrhea, bleeding, abdominal pain and weight loss) after failure, refractoriness, relapse or intolerance to anti-TNF therapy.
UAT 172 – Risankizumab
(Analysis of the Public Participation contributions)
2pm to 4pm
UAT 178 – Concomitant exclusion of the left atrial appendage by surgical clip
(Preliminary Discussion)
Treatment of patients with atrial fibrillation (characterized by irregular heartbeats) or at high risk of stroke, as measured by the CHA2DS2-VASc score ≥ 2, undergoing open heart surgery
Nov 26, 2025
Discussion of the proposals for inclusion in the List of Health Procedures and Events (Rol), concerning the following technologies:
SESSION
TECHNOLOGY
INDICATION FOR USE
9am to 12pm
UAT 182 – Enzalutamide in combination with deprivation therapy
(Preliminary Discussion)
Treatment of non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence
UAT 184 – Proposal to amend the Guideline for Use – DUT 110 – Molecular DNA analysis
Subitem 110.39 – Submicroscopic chromosomal abnormality syndromes not clinically recognizable
(Preliminary Discussion)
Diagnosis of intellectual disability of undetermined cause
2pm to 4pm
UAT 179 – Cabozantinib levomalate
(Preliminary Discussion)
Treatment of well-differentiated, unresectable, locally advanced or metastatic neuroendocrine tumors previously treated with two or more therapies
https://www.gov.br/ans/pt-br/assuntos/noticias/sociedade/cosaude-realiza-46a-reuniao-tecnica
Open public consultations
- CP 163. Its purpose is to receive contributions on the proposals to update the List of Health Procedures and Events (Rol), specifically on the preliminary recommendation of non-incorporation for the technologies contained in UAT No. 171 – Inclisiran, UAT No. 175 – Lebrikizumab and UAT No. 176 – Momelotinib. Deadline: Nov 5, 2025 to Nov 24, 2025
Scheduled public hearings
- Public Hearing No. 61, collection of contributions on the preliminary recommendation of non-incorporation for the following technologies:
(i) UAT 171 – Inclisiran for the treatment of primary hypercholesterolemia or mixed dyslipidemia;
(ii) UAT 175 – Lebrikizumab for the treatment of adult patients with severe atopic dermatitis who have failed, are intolerant to, or have a contraindication to cyclosporine; and
(iii) UAT 176 – Momelotinib for the treatment of intermediate- and high-risk myelofibrosis.
Date: November 19, 2025, from 9am to 1pm.
Open public calls for input
There are no open public calls for input.
Open public calls
No updates.
Other news
Unimed Ferj and Unimed do Brasil strike a deal to try to end the care crisis
Source: oglobo.globo.com · read the full article
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.